Technical Analysis for CARA - Cara Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
16.55 | 0.06% | 0.01 |
CARA closed down 2.13 percent on Wednesday, February 20, 2019, on 79 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| See historical CARA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Feb 20 | Stochastic Sell Signal | Bearish | 0.06% |
| Feb 20 | Slingshot Bullish | Bullish Swing Setup | 0.06% |
| Feb 20 | Overbought Stochastic | Strength | 0.06% |
| Feb 19 | NR7 | Range Contraction | -2.07% |
| Feb 19 | NR7-2 | Range Contraction | -2.07% |
| Feb 19 | Upper Bollinger Band Walk | Strength | -2.07% |
| Feb 19 | Overbought Stochastic | Strength | -2.07% |
| Feb 19 | Upper Bollinger Band Touch | Strength | -2.07% |
| Feb 15 | Calm After Storm | Range Contraction | -2.93% |
| Feb 15 | NR7 | Range Contraction | -2.93% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-21
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Chemistry Health Biopharmaceutical Pain Clinical Trial Piperidines Amines Mesoblast Trevena Inc
Chemistry Health Biopharmaceutical Pain Clinical Trial Piperidines Amines Mesoblast Trevena Inc
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CARA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 24.3 |
| 52 Week Low | 11.46 |
| Average Volume | 671,015 |
| 200-Day Moving Average | 17.6507 |
| 50-Day Moving Average | 15.0496 |
| 20-Day Moving Average | 15.781 |
| 10-Day Moving Average | 16.431 |
| Average True Range | 0.7188 |
| ADX | 23.62 |
| +DI | 25.0974 |
| -DI | 16.0013 |
| Chandelier Exit (Long, 3 ATRs ) | 15.2036 |
| Chandelier Exit (Short, 3 ATRs ) | 16.2564 |
| Upper Bollinger Band | 17.3384 |
| Lower Bollinger Band | 14.2236 |
| Percent B (%b) | 0.74 |
| BandWidth | 19.737659 |
| MACD Line | 0.421 |
| MACD Signal Line | 0.2952 |
| MACD Histogram | 0.1258 |
| Fundamentals | Value |
|---|---|
| Market Cap | 538.88 Million |
| Num Shares | 32.6 Million |
| EPS | -2.28 |
| Price-to-Earnings (P/E) Ratio | -7.25 |
| Price-to-Sales | 424.16 |
| Price-to-Book | 3.54 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.49 | ||||
| Resistance 3 (R3) | 17.50 | 17.21 | 17.33 | ||
| Resistance 2 (R2) | 17.21 | 16.97 | 17.20 | 17.27 | |
| Resistance 1 (R1) | 16.87 | 16.82 | 16.73 | 16.86 | 17.22 |
| Pivot Point | 16.58 | 16.58 | 16.50 | 16.57 | 16.58 |
| Support 1 (S1) | 16.24 | 16.34 | 16.10 | 16.23 | 15.86 |
| Support 2 (S2) | 15.95 | 16.19 | 15.94 | 15.81 | |
| Support 3 (S3) | 15.61 | 15.95 | 15.75 | ||
| Support 4 (S4) | 15.60 |
